The Endpoints 100: Novartis gets 'poor' grade on data scandal, Ned Sharpless isn't a 'wow' and that Canada drug importation plan is a nonstarter
Novartis’ latest scandal revolving around hidden data manipulation has become a cautionary tale for the biopharma industry — and one that offers clear guidelines on doing the right thing.
That is just one of the inevitable conclusions to be reached from our latest survey of the Endpoints 100, which tracks the opinion of a global group of senior executives in the industry — who share some sharp observations on where we are headed in biopharma.
Uniformity is clearly out when it comes to the E100, but it’s easy to see which way the wind is blowing for the majority of the 74 execs who participated in the latest round.
In addition to the hot button issues we surveyed the group on, we’re seeing plenty of hiring continue at these companies — not unexpected in a field that has seen a decade of rapid growth. But while most continue to see the financial environment we’re in now as a positive — with access to capital, a “warm” environment for M&A and good valuations — there’s also been a distinct reduction in the fervor that’s being felt here.
That cooling enthusiasm may not be unexpected at a time when stock valuations for a host of players have been beaten up some — or a lot. But the fundamentals all still look rock-solid, for now.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.